Given that women with breast cancer are commonly treated with doxorubicin and that our initial genetic studies identified TRPC6 genetic variants as associated with a decline in LVEF in women with breast cancer (19), in this study we also assessed female mice treated with the same dose of doxorubicin as the dose given to males. Here, TRPC6 is linked to breast carcinoma.